诺华公司Novartis AG (NVS) 2017年CSR报告「NYSE」.pdf

1、Corporate Responsibility Report2017 Cover photo Adiarra Traore undergoes a health check at the Bougoula-Hameau clinic in Mali,West Africa,as part of a clinical trial to assess an experimental medicine for malaria called KAF156,being developed by Novartis and several partner organizations.2Novartis C

2、orporate Responsibility Report 2017|ContentsContents2017 HIGHLIGHts 3ABoUt noVARtIs 5MessAGe FRoM tHe CHAIRMAn 6tHRee QUestIons to tHe Ceo AnD tHe GLoBAL HeAD oF CR 8CoRPoRAte ResPonsIBILItY AtnoVARtIs 10Novartis and the UN Sustainable Development Goals 10Governance of our corporate responsibility a

3、ctivities 10Setting priorities 2017 materiality assessment 11Stakeholder engagement 13Improving transparency 14Financial,environmental and social impact valuation 14ACCess to HeALtHCARe 17Availability of medicines 19Pricing 20Intellectual property 21Healthcare system strengthening 21Patient assistan

4、ce programs 23InnoVAtIon 25R&D for unmet medical needs 27R&D for neglected diseases 27Drug resistance 27Business model innovation 28Innovative technologies 29PAtIent HeALtH AnD sAFetY 30Pharmacovigilance,safety profile and quality of drugs 31Health education and prevention 32Counterfeit medicines 34

5、etHICAL BUsIness PRACtICes 35Ethical and compliant behavior 36Responsible supply chain management 38Respect for human rights 40Responsible use of new technologies 41Animal testing 42ABoUt tHIs RePoRt 44Performance indicators 2017 45Novartis GRI Content Index 49Appendix:external initiatives and membe

6、rship of associations 55Appendix:corporate responsibility issue cluster andtopic definitions 56Novartis and the UnitedNationsGlobalCompact 58Independent Assurance Report ontheNovartis 2017 corporateresponsibility reporting 603Novartis Corporate Responsibility Report 2017|2017 HIGHLIGHts2017 highligh